Moreover, targeting LYPD3 (LY6/PLAUR domain containing 3), which is regulated downstream of FOXA1 and GRHL2, can reduce tumor proliferation in cases that resist endocrine treatments. The gene discussed is LYPD3; the disease is neoplasm.